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2352-3964/© 2017 The Authors. Published by Elsevier B.VCrohn's disease (CD) is a common form of chronic inﬂammatory
bowel disease (IBD) affecting 21–294 per 100,000 in European popula-
tions (Cosnes et al., 2011). It arises most likely from an interaction be-
tween genetic and environmental factors leading to an aberrant
immune response to the gut microbiota. Previous genome-wide associa-
tion studies have describedmore than 200 genetic loci that are associated
with IBD (Liu et al., 2015).NOD2 (nucleotide-binding oligomerisation do-
main containing 2), an intracellular sensor of bacteria-derived muramyl
dipeptide, was the ﬁrst genetic association discovered in CD and remains
one of the strongest associations (Knights et al., 2013). The mechanisms
whereby NOD2mutations result in intestinal inﬂammation in CD remain
incompletely understood. Evidence suggests that NOD2mutations are as-
sociatedwith a loss of innate immune protectivemechanisms in both cir-
culating antigen presenting cells and in the intestine (Van Heel et al.,
2006). The three main reported disease-associated polymorphisms
(R702W, G908R, and 1007fs) all contribute to disease pathogenesis
through interference with bacterial recognition (Van Heel et al., 2006).
Several environmental factors have been postulated in CD, but the
most consistent epidemiological evidence points to a clear risk associat-
ed with cigarette smoking. Two meta-analyses reveal that current
smokers are up to twice as likely to develop CD as non-smokers (OR
= 1.8–2.0) (Mahid et al., 2006). Cigarette smoking can impair both in-
nate and adaptive immune responses, thereby increasing susceptibility
tomicrobial infectionswhichwould support its role in the pathogenesis
of CD (Sopori, 2002).
The role of genetics and environmental contribution to the aetiology
of CD has been the subject of much research over the past decade. It has
been reported that cigarette smoke extract can delay NOD2mRNA ex-
pression leading to the impairment of NOD2 functioning in intestinal
epithelial cells (Helbig et al., 2012).
Given the established roles of NOD2 and cigarette smoking on innate
immunity, it is conceivable that cigarette smoking might modulate the
functional consequences of CD-associated polymorphism in NOD2
(Helbig et al., 2012).
Kuenzig et al. (2017)) describe a study of the interaction of smoking
and one of three loss-of-function risk variants in the NOD2 gene
(1007fs). This is the ﬁrst comprehensive systematic review and meta-
analysis of the interaction between NOD2 and cigarette smoking in CD.om.2017.06.012.
y).
. This is an open access article underWhilst it is clear that smoking and NOD2 variants increase the risk of CD
independently, there is conﬂicting evidence for their interaction with
some studies suggesting a positive interaction, a negative interaction or
no interaction. The discordant ﬁndings could be explained by the fact
that themajority of previousNOD2/smoking studieswere underpowered
to detect an interaction. Based on a large literature review andmeta-anal-
ysis, the authors conclude that only one of the three known CD risk vari-
ants in NOD2 (1007fs) shows an interaction with smoking exposure and
more importantly, this interaction is negative. They subsequently explore
this relationship inmore detail in a case series of 627 patients which con-
ﬁrms the negative interaction. They suggest this is due to the inverse re-
lationship between NOD2 prevalence (increased in younger patients
with CD) and smoking exposure (increased in older patients with CD)
with increasing age of onset. It is important to point out that the authors
could not restrict their analysis to individual age groups and hence, they
were not able to adjust age as a confounder. However, a similar signiﬁcant
negative interaction between smoking and NOD2 was demonstrated in a
previous study byHelbig et al. (2012) even after adjusting for age at diag-
nosis. They concluded that the risk increase for CD conferred simulta-
neously by cigarette smoking and the 1007fs NOD2 polymorphism is
smaller than expected under a multiplicative model.
The complexity of identifying gene-environment interactions for
Crohn's disease should be acknowledged. It is important to understand
the design of the studies and the methodical implications of grouping
multiple genetic variants into a single analysis. Helbig et al. were the
ﬁrst to use a case-only design to explore statistical interaction and the
current meta-analysis adopted a similar design. Amultiplicative interac-
tion as demonstrated here does not indicate which group is at a higher
absolute risk from the environmental exposure; case-only studies cannot
be used to assess for additive interactions, and it remains possible that
the absolute risk of smoking in NOD2 variant carriers would be higher
than in those with wild-type NOD2 (Greenland et al., 2008).
The similar results obtained from the two quoted studies are intrigu-
ing and point to the importance of assessing genetic and environmental
factors in sub-phenotypes of CD. In addition to age, disease location, dis-
ease behaviour and other subphenotypes may inﬂuence gene-environ-
ment interactions. Both NOD2 and smoking are associated with ileal CD
and furthermore, ileal and colonic CD have been shown to be in part ge-
netically-determined phenotypes (Cleynen et al., 2016).
Further epidemiological and functional studies are needed to fully ex-
plore the mechanistic gene-environment interactions in patients with
CD. They need to be adequately powered to assess SNP-speciﬁcthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
50 N. Heerasing, N.A. Kennedy / EBioMedicine 21 (2017) 49–50interactions. The current meta-analysis provides a platform for further
research in the ﬁeld of precision medicine which will enable clinicians
to develop personalised recommendations for individuals at high risk
of developing CD.
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